在全球范围内，伊普可泮在2023年12月获得美国FDA批准上市，成为治疗成人阵发性夜间血红蛋白尿症（PNH）的首个口服单药疗法。今年8月8日，FDA再次批准伊普可泮新适应症，用于降低成人IgA肾病（IgAN）患者的蛋白尿水平，这些患者有疾病迅速进展的 ...

Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs.

Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...

每经AI快讯，有投资者在投资者互动平台提问：请问吉利德是否为公司重要客户？有提供了哪些产品和服务吗？谢谢 九洲药业（603456.SH）9月20日在投资者互动平台表示，公司服务客户包括 ...

Novartis announced this week that the FDA has approved ribociclib (marketed as Kisqali) for the treatment of people with ...

Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous ...

Novartis AG’s breast cancer drug helped prevent the disease coming back a year after treatment had ended, in new data that ...

Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease.

The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early ...

Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy1,2 Kisqali® ...